BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 23791573)

  • 1. The challenge of Bacillus Calmette-Guérin failure in nonmuscle invasive bladder cancer--what is the next step in management?
    Lotan Y
    J Urol; 2013 Sep; 190(3):832-3. PubMed ID: 23791573
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial comment on: Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy.
    de Reijke TM
    Eur Urol; 2009 Jun; 55(6):1395-6. PubMed ID: 19193488
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and safety of photodynamic therapy for recurrent, high grade nonmuscle invasive bladder cancer refractory or intolerant to bacille Calmette-Guérin immunotherapy.
    Lee JY; Diaz RR; Cho KS; Lim MS; Chung JS; Kim WT; Ham WS; Choi YD
    J Urol; 2013 Oct; 190(4):1192-9. PubMed ID: 23648222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy.
    Ayari C; LaRue H; Hovington H; Decobert M; Harel F; Bergeron A; Têtu B; Lacombe L; Fradet Y
    Eur Urol; 2009 Jun; 55(6):1386-95. PubMed ID: 19193487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
    Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
    Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder.
    Berglund RK; Savage CJ; Vora KC; Kurta JM; Cronin AM
    J Urol; 2008 Oct; 180(4):1297-300; discussion 1300. PubMed ID: 18707737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Editorial comment on: Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder cancer.
    Evans CP
    Eur Urol; 2007 Oct; 52(4):1129-30. PubMed ID: 17383082
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase I trial of intravesical recombinant adenovirus mediated interferon-α2b formulated in Syn3 for Bacillus Calmette-Guérin failures in nonmuscle invasive bladder cancer.
    Dinney CP; Fisher MB; Navai N; O'Donnell MA; Cutler D; Abraham A; Young S; Hutchins B; Caceres M; Kishnani N; Sode G; Cullen C; Zhang G; Grossman HB; Kamat AM; Gonzales M; Kincaid M; Ainslie N; Maneval DC; Wszolek MF; Benedict WF
    J Urol; 2013 Sep; 190(3):850-6. PubMed ID: 23507396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective comparative study of intravesical bacillus Calmette-Guérin therapy with the Tokyo or Connaught strain for nonmuscle invasive bladder cancer.
    Sengiku A; Ito M; Miyazaki Y; Sawazaki H; Takahashi T; Ogura K
    J Urol; 2013 Jul; 190(1):50-4. PubMed ID: 23376145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
    Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
    J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update.
    Hall MC; Chang SS; Dalbagni G; Pruthi RS; Seigne JD; Skinner EC; Wolf JS; Schellhammer PF
    J Urol; 2007 Dec; 178(6):2314-30. PubMed ID: 17993339
    [No Abstract]   [Full Text] [Related]  

  • 12. A phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of bacillus Calmette-Guérin refractory nonmuscle invasive bladder cancer.
    McKiernan JM; Barlow LJ; Laudano MA; Mann MJ; Petrylak DP; Benson MC
    J Urol; 2011 Aug; 186(2):448-51. PubMed ID: 21680003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of intravesical nanoparticle albumin bound paclitaxel for the treatment of nonmuscle invasive urothelial carcinoma of the bladder after bacillus Calmette-Guérin treatment failure.
    McKiernan JM; Holder DD; Ghandour RA; Barlow LJ; Ahn JJ; Kates M; Badalato GM; Roychoudhury A; Decastro GJ; Benson MC
    J Urol; 2014 Dec; 192(6):1633-8. PubMed ID: 24996128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
    Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
    Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T1 Substaging of Nonmuscle Invasive Bladder Cancer is Associated with bacillus Calmette-Guérin Failure and Improves Patient Stratification at Diagnosis.
    de Jong FC; Hoedemaeker RF; Kvikstad V; Mensink JTM; de Jong JJ; Boevé ER; van der Schoot DKE; Zwarthoff EC; Boormans JL; Zuiverloon TCM
    J Urol; 2021 Mar; 205(3):701-708. PubMed ID: 33191862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bacillus Calmette-Guerin-refractory superficial bladder cancers: focus on pretreatment episodes.
    Okamura T; Akita H; Tozawa K; Kawai N; Nagata D; Kohri K
    Int J Clin Oncol; 2003 Jun; 8(3):168-73. PubMed ID: 12851841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow-up of intravesical bacillus Calmette-Guérin treatment for superficial transitional-cell carcinoma of the bladder involving the prostatic urethra.
    Taylor JH; Davis J; Schellhammer P
    Clin Genitourin Cancer; 2007 Sep; 5(6):386-9. PubMed ID: 17956711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.
    Friedrich MG; Pichlmeier U; Schwaibold H; Conrad S; Huland H
    Eur Urol; 2007 Oct; 52(4):1123-29. PubMed ID: 17383080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
    Wo JY; Shipley WU; Dahl DM; Coen JJ; Heney NM; Kaufman DS; Zietman AL
    BJU Int; 2009 Jul; 104(2):179-83. PubMed ID: 19154448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [International Consensus Panel--treatment strategies for superficial bladder cancer].
    Adler S; St Niclas M
    Aktuelle Urol; 2006 Sep; 37(5):320-3; discussion 322-3. PubMed ID: 17004179
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.